ClinicalTrials.gg
CompletedNCT00817050Updated Aug 15, 2024

Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)

A Phase 4 interventional study of Mometasone Furoate Nasal Spray and fluticasone nasal spray in Allergic Rhinitis, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Dec 2004, registered Jan 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 34 studies testing fluticasone in Rhinitis, Allergic — none open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic.

Enrollment
14th of 34
100 · median 63
Started
2004
with 2 others
Phase 4
19 of 34
none open now
Registered
15th of 34
by date
Lead sponsor
2 of 34
Organon and Co

Among the 34 studies testing fluticasone in Rhinitis, Allergic, this one is the 14th largest by enrollment, is one of 3 that started in 2004, is one of 19 in phase 4, and was the 15th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

None of the 34 studies testing fluticasone in Rhinitis, Allergic is open now. The open studies under Rhinitis, Allergic, anywhere →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing fluticasone in Rhinitis, Allergic as a file.
02

Study summary

This was a one-day single dose trial conducted to compare patient's preference for Nasonex® (mometasone) versus Flonase® nasal spray. Each patient was randomized to take one dose (2 sprays in each nostril) of Nasonex or Flonase. Thirty minutes later, each patient was to take one dose of the opposite medication. Questionnaires were given to each patient after each drug dose to evaluate patient product preference.

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have been 18-65 years of age, of either sex and any race.
  • Subject must have had symptomatic allergic rhinitis with a total nasal symptom (congestion, rhinorrhea, sneezing, itching) severity score of \<6 but >2; congestion must have been \<2.
  • Subject must have been free of any disease (other than allergic rhinitis) that would interfere with study evaluations.
  • Subject must have understood and been able to adhere to the dosing and visit schedule.

Exclusion criteria

Exclusion Criteria:

  • Subject had used any product within 30 days prior to enrollment.
  • Subject was in a situation or condition that, in the opinion of the investigator, may have interfered with optimal participation in the study.
  • Subject was participating in any other clinical study(ies).
  • Subject was using any nasal lavage fluid or spray.
  • Subject was using any perfume during the study day.
  • Subject was using any oral rinse during the study day.
  • Subject had used topical or oral nasal decongestants in the past 1 week.
  • Subject had used a nasal in the previous 2 weeks.
  • Subject had anosmia or ageusia (absence of the sense of smell or taste).
  • Subject had been using medications which are associated with anosmia or ageusia in the 2 weeks prior to testing.
  • Subject had a respiratory infection in the 2 weeks prior to testing.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Nasonex Followed by Flonase

    Drug: Mometasone Furoate Nasal Spray · Drug: fluticasone nasal spray

  • Active comparator
    Flonase Followed by Nasonex

    Drug: Mometasone Furoate Nasal Spray · Drug: fluticasone nasal spray

Interventions

06

What researchers measure

Primary outcomes

  1. Overall product preference based on subjects' answer to the question "which product do you prefer overall"

    Time frame: On the study day, after dose of each product

Secondary outcomes

  1. Subject rating for likely compliance with daily dosing,

    Time frame: On the study day, after dose of each product

  2. Subject preference for glass or plastic bottle

    Time frame: On the study day, after dose of each product

  3. Subject response to if they would want a prescription for their preferred product and if they would recommend the product

    Time frame: On the study day, after dose of each product

  4. Subject response to whether they preferred inhaled corticosteroid with or without aftertaste, and/or scent/odor,

    Time frame: On the study day, after dose of each product

  5. Subject ratings for individual product attributes

    Time frame: On the study day, after dose of each product

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2004 to primary completion in Jan 2005, 1 month.

Of 34 phase 4 interventional studies under Rhinitis, Allergic, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 38. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2009
First posted
Jan 6, 2009
StartActual
Dec 1, 2004
Primary completionActual
Jan 1, 2005
CompletionActual
Jan 1, 2005
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00817050
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 6, 2009
Start date
Dec 1, 2004
Primary completion
Jan 1, 2005
Completion
Jan 1, 2005
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion